Carboplatin

Carboplatin
Clinical data
Pronunciation/ˈkɑːrboʊˌplætən/
Trade namesParaplatin, others
AHFS/Drugs.comMonograph
MedlinePlusa695017
Routes of
administration		Intravenous
ATC code
  • L01XA02 (WHO) ]
Legal status
Legal status
  • AU: S4 (Prescription only)[1]
  • CA: ℞-only[2]
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailabilitycomplete
Protein bindingVery low
Elimination half-life1.1-2 hours
ExcretionKidney
Identifiers
IUPAC name
  • cis-diammine(cyclobutane-1,1-dicarboxylate-O,O')platinum(II)
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.050.388
Chemical and physical data
FormulaC6H12N2O4Pt
Molar mass371.256 g·mol−1
3D model (JSmol)
SMILES
  • C1CC2(C1)C(=O)O[Pt-2]([NH3+])([NH3+])OC2=O
  • InChI=1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2 Y
  • Key:OLESAACUTLOWQZ-UHFFFAOYSA-L Y
 NY (what is this?)  (verify)

Carboplatin, sold under the brand name Paraplatin among others, is a chemotherapy medication used to treat a number of forms of cancer.[3] This includes ovarian cancer, lung cancer, head and neck cancer, brain cancer, and neuroblastoma.[3] It is administered by injection into a vein sometimes via a port.[3]

Side effects generally occur.[3] Common side effects include low blood cell levels, nausea, and electrolyte problems.[4][3] Other serious side effects include allergic reactions and mutagenesis. It may be carcinogenic, but further research is needed to confirm this.[3] Use during pregnancy may result in harm to the baby.[3] Carboplatin is in the platinum-based antineoplastic family of medications and works by interfering with duplication of DNA.[3][5]

Carboplatin was developed as a less toxic analogue of cisplatin.[6] It was patented in 1972 and approved for medical use in 1989.[7] It is on the 2023 World Health Organization's List of Essential Medicines.[8]

  1. ^ https://www.tga.gov.au/resources/prescription-medicines-registrations/carboplatin-epsl-eugia-pharma-australia-pty-ltd
  2. ^ "Product monograph brand safety updates". Health Canada. 7 July 2016. Retrieved 3 April 2024.
  3. ^ a b c d e f g h "Carboplatin". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
  4. ^ Oun R, Moussa YE, Wheate NJ (May 2018). "The side effects of platinum-based chemotherapy drugs: a review for chemists". Dalton Transactions. 47 (19): 6645–6653. doi:10.1039/c8dt00838h. PMID 29632935.
  5. ^ Apps MG, Choi EH, Wheate NJ (August 2015). "The state-of-play and future of platinum drugs". Endocrine-Related Cancer. 22 (4): R219 – R233. doi:10.1530/ERC-15-0237. hdl:2123/24426. PMID 26113607.
  6. ^ Cite error: The named reference lebwohl was invoked but never defined (see the help page).
  7. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 513. ISBN 9783527607495. Archived from the original on 20 December 2016.
  8. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.